|
Video: What is a Stock Split?
|
|
Lumos Pharma is a clinical-stage biopharmaceutical company. Co. is engaged in developing its clinical program and focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Co.'s pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone is approved. Co. has two small-molecule product candidates, which include indoximod, NLG802 (a prodrug of indoximod) and NLG919 (a direct IDO1 enzymatic inhibitor) that are indoleamine-2, 3-dioxygenase pathway inhibitors. According to our LUMO split history records, Lumos Pharma has had 0 splits. | |
|
Lumos Pharma (LUMO) has 0 splits in our LUMO split history database.
Looking at the LUMO split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lumos Pharma shares, starting with a $10,000 purchase of LUMO, presented on a split-history-adjusted basis factoring in the complete LUMO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$27.98 |
|
End price/share: |
$2.82 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-89.92% |
|
Average Annual Total Return: |
-20.51% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,007.86 |
|
Years: |
10.00 |
|
|
|
|
|